Protective Efficacy of P7C3-S243 in the 6-hydroxydopamine Model of Parkinson's Disease

Overview

Journal NPJ Parkinsons Dis

Date 2016 May 10

PMID 27158662

Citations 30

Authors

Hector De Jesus-Cortes

Adam D Miller

Jeremiah K Britt

Anthony J DeMarco

Mayralis De Jesus-Cortes

Emily Stuebing

Jacinth Naidoo

Edwin Vazquez-Rosa

Lorraine Morlock

Noelle S Williams

Joseph M Ready

Nandakumar S Narayanan

Andrew A Pieper

Affiliations

Soon will be listed here.

Abstract

Background: There are currently no therapeutic options for patients with Parkinson's disease that prevent or slow the death of dopaminergic neurons. We have recently identified the novel P7C3 class of neuroprotective molecules that blocks neuron cell death.

Aims: The aim of this study was to determine whether treatment with highly active members of the P7C3 series blocks dopaminergic neuron cell death and associated behavioral and neurochemical deficits in the rat 6-hydroxydopamine (6-OHDA) model of Parkinson's disease.

Methods: After unilateral injection of 6-OHDA into the median forebrain bundle, rats were assessed for behavioral function in the open field, cylinder test, and amphetamine-induced circling test. Thereafter, their brains were subjected to neurochemical and immunohistochemical analysis of dopaminergic neuron survival. Analysis was conducted as a function of treatment with P7C3 compounds, with administration initiated either before or after 6-OHDA exposure.

Results: Animals administered P7C3-A20 or P7C3-S243, two of the most advanced agents in the P7C3 series of neuroprotective compounds, both before and after 6-OHDA exposure showed evidence of protective efficacy in all measures. When P7C3-S243 administration was initiated after 6-OHDA exposure, rats also showed protective efficacy in all measures, which included blocking dopaminergic neuron cell death in ipsilateral substantia nigra pars compacta, preservation of dopamine and its metabolites in ipsilateral striatum, and preservation of normal motor behavior.

Conclusions: The P7C3 series of compounds may form the basis for developing new therapeutic agents for slowing or preventing progression of Parkinson's disease.

Citing Articles

P7C3 suppresses astrocytic senescence to protect dopaminergic neurons: Implication in the mouse model of Parkinson's disease.

Chen Y, Zhu Z, Yan Y, Sun H, Wang G, Du X CNS Neurosci Ther. 2024; 30(7):e14819.

PMID: 39056208 PMC: 11273101. DOI: 10.1111/cns.14819.

A Multifunctional Therapeutic Strategy Using P7C3 as A Countermeasure Against Bone Loss and Fragility in An Ovariectomized Rat Model of Postmenopausal Osteoporosis.

Wei F, Hughes M, Omer M, Ngo C, Pugazhendhi A, Kolanthai E Adv Sci (Weinh). 2024; 11(21):e2308698.

PMID: 38477537 PMC: 11151083. DOI: 10.1002/advs.202308698.

Higher concentration of P7C3 than required for neuroprotection suppresses renal cell carcinoma growth and metastasis.

Shu G, Chen W, Huang C, Shan H, Ye J, Li J J Cancer. 2024; 15(5):1191-1202.

PMID: 38356717 PMC: 10861821. DOI: 10.7150/jca.90439.

P7C3 Ameliorates Bone Loss by Inhibiting Osteoclast Differentiation and Promoting Osteogenesis.

Tian B, Bai J, Sheng L, Chen H, Chang W, Zhang Y JBMR Plus. 2023; 7(12):e10811.

PMID: 38130773 PMC: 10731119. DOI: 10.1002/jbm4.10811.

Application of P7C3 Compounds to Investigating and Treating Acute and Chronic Traumatic Brain Injury.

Sridharan P, Miller E, Pieper A Neurotherapeutics. 2023; 20(6):1616-1628.

PMID: 37651054 PMC: 10684439. DOI: 10.1007/s13311-023-01427-8.

References

Naidoo J, De Jesus-Cortes H, Huntington P, Estill S, Morlock L, Starwalt R . Discovery of a neuroprotective chemical, (S)-N-(3-(3,6-dibromo-9H-carbazol-9-yl)-2-fluoropropyl)-6-methoxypyridin-2-amine [(-)-P7C3-S243], with improved druglike properties. J Med Chem. 2014; 57(9):3746-54. PMC: 4206694. DOI: 10.1021/jm401919s. View

Wang G, Han T, Nijhawan D, Theodoropoulos P, Naidoo J, Yadavalli S . P7C3 neuroprotective chemicals function by activating the rate-limiting enzyme in NAD salvage. Cell. 2014; 158(6):1324-1334. PMC: 4163014. DOI: 10.1016/j.cell.2014.07.040. View

Johnston L, Su X, Maguire-Zeiss K, Horovitz K, Ankoudinova I, Guschin D . Human interleukin-10 gene transfer is protective in a rat model of Parkinson's disease. Mol Ther. 2008; 16(8):1392-9. PMC: 2725180. DOI: 10.1038/mt.2008.113. View

Dutca L, Stasheff S, Hedberg-Buenz A, Rudd D, Batra N, Blodi F . Early detection of subclinical visual damage after blast-mediated TBI enables prevention of chronic visual deficit by treatment with P7C3-S243. Invest Ophthalmol Vis Sci. 2014; 55(12):8330-41. PMC: 5102342. DOI: 10.1167/iovs.14-15468. View

Robinson T, Noordhoorn M, Chan E, Mocsary Z, Camp D, Whishaw I . Relationship between asymmetries in striatal dopamine release and the direction of amphetamine-induced rotation during the first week following a unilateral 6-OHDA lesion of the substantia nigra. Synapse. 1994; 17(1):16-25. DOI: 10.1002/syn.890170103. View

Kemp S, Szynkaruk M, Stanoulis K, Wood M, Liu E, Willand M . Pharmacologic rescue of motor and sensory function by the neuroprotective compound P7C3 following neonatal nerve injury. Neuroscience. 2014; 284:202-216. DOI: 10.1016/j.neuroscience.2014.10.005. View

Pieper A, Xie S, Capota E, Estill S, Zhong J, Long J . Discovery of a proneurogenic, neuroprotective chemical. Cell. 2010; 142(1):39-51. PMC: 2930815. DOI: 10.1016/j.cell.2010.06.018. View

Sarre S, Yuan H, Jonkers N, Van Hemelrijck A, Ebinger G, Michotte Y . In vivo characterization of somatodendritic dopamine release in the substantia nigra of 6-hydroxydopamine-lesioned rats. J Neurochem. 2004; 90(1):29-39. DOI: 10.1111/j.1471-4159.2004.02471.x. View

Schober A . Classic toxin-induced animal models of Parkinson's disease: 6-OHDA and MPTP. Cell Tissue Res. 2004; 318(1):215-24. DOI: 10.1007/s00441-004-0938-y. View

10.

Tesla R, Wolf H, Xu P, Drawbridge J, Estill S, Huntington P . Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 2012; 109(42):17016-21. PMC: 3479516. DOI: 10.1073/pnas.1213960109. View

11.

Pieper A, McKnight S, Ready J . P7C3 and an unbiased approach to drug discovery for neurodegenerative diseases. Chem Soc Rev. 2014; 43(19):6716-26. PMC: 4237066. DOI: 10.1039/c3cs60448a. View

12.

Tetrault S, Chever O, Sik A, Amzica F . Opening of the blood-brain barrier during isoflurane anaesthesia. Eur J Neurosci. 2008; 28(7):1330-41. DOI: 10.1111/j.1460-9568.2008.06443.x. View

13.

Schallert T, Fleming S, Leasure J, Tillerson J, Bland S . CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury. Neuropharmacology. 2000; 39(5):777-87. DOI: 10.1016/s0028-3908(00)00005-8. View

14.

Dittmar M, Petermichl W, Schlachetzki F, Graf B, Gruber M . Isoflurane induces endothelial apoptosis of the post-hypoxic blood-brain barrier in a transdifferentiated human umbilical vein endothelial cell model. PLoS One. 2012; 7(6):e38260. PMC: 3377664. DOI: 10.1371/journal.pone.0038260. View

15.

Yin T, Britt J, De Jesus-Cortes H, Lu Y, Genova R, Khan M . P7C3 neuroprotective chemicals block axonal degeneration and preserve function after traumatic brain injury. Cell Rep. 2014; 8(6):1731-1740. PMC: 4206693. DOI: 10.1016/j.celrep.2014.08.030. View

16.

MacMillan K, Naidoo J, Liang J, Melito L, Williams N, Morlock L . Development of proneurogenic, neuroprotective small molecules. J Am Chem Soc. 2011; 133(5):1428-37. PMC: 3033481. DOI: 10.1021/ja108211m. View

17.

Asai-Coakwell M, March L, Dai X, Duval M, Lopez I, French C . Contribution of growth differentiation factor 6-dependent cell survival to early-onset retinal dystrophies. Hum Mol Genet. 2013; 22(7):1432-42. DOI: 10.1093/hmg/dds560. View

18.

Walker A, Rivera P, Wang Q, Chuang J, Tran S, Osborne-Lawrence S . The P7C3 class of neuroprotective compounds exerts antidepressant efficacy in mice by increasing hippocampal neurogenesis. Mol Psychiatry. 2014; 20(4):500-8. PMC: 4206684. DOI: 10.1038/mp.2014.34. View

19.

De Jesus-Cortes H, Xu P, Drawbridge J, Estill S, Huntington P, Tran S . Neuroprotective efficacy of aminopropyl carbazoles in a mouse model of Parkinson disease. Proc Natl Acad Sci U S A. 2012; 109(42):17010-5. PMC: 3479520. DOI: 10.1073/pnas.1213956109. View

20.

Cao Y, Ni C, Li Z, Li L, Liu Y, Wang C . Isoflurane anesthesia results in reversible ultrastructure and occludin tight junction protein expression changes in hippocampal blood-brain barrier in aged rats. Neurosci Lett. 2014; 587:51-6. DOI: 10.1016/j.neulet.2014.12.018. View